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Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has led to  
a paradigm shift in healthcare worldwide. Little is known about the impact on the cardiovascular 
system, and the incidence and consequences of new onset of atrial fibrillation (AF) in infected patients 
remain unclear. The aim of this study was to analyze the cardiovascular outcomes of patients with new-
onset AF and coronavirus disease 2019 (COVID-19) infection.
Methods: This observational study analyzed a sample of 160 consecutive patients hospitalized due to 
COVID-19. A group with new-onset AF (n = 12) was compared with a control group (total: n = 148,  
sinus rhythm: n = 118, previous AF: n = 30). New-onset AF patients were significantly older and 
hypertensive, as well as presenting more frequently with a history of acute coronary syndrome and 
renal dysfunction. This group showed a higher incidence of thromboembolic events (41.7% vs. 4.1%;  
p < 0.001), bleeding (33.3% vs. 4.7%, p = 0.005), a combined endpoint of thrombosis and death  
(58.3% vs. 19.6%, p = 0.006) and longer hospital stays (16.4 vs. 8.6 days, p < 0.001), with no differ-
ences in all-cause mortality.
Results: In multivariate analysis, adjusted by potential confounding factors, new-onset AF demon-
strated a 14.26 odds ratio for thromboembolism (95% confidence interval 2.86–71.10, p < 0.001).
Conclusions: New-onset AF in COVID-19 patients presumably has a notable impact on prognosis. 
The appearance of new-onset AF is related to worse cardiovascular outcomes, considering it as an in-
dependent predictor of embolic events. Further studies are needed to identify patients with COVID-19 
at high risk of developing “de novo” AF, provide early anticoagulation and minimize the embolic risk of 
both entities. (Cardiol J 2021; 28, 1: 34–40)
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Introduction
Coronavirus disease 2019 (COVID-19), a viral 
respiratory illness caused by severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2), has 
caused a pandemic which is overwhelming health 
care systems worldwide. Affected patients have 
been reported to have an inflammatory state that 
may predispose patients to in-hospital cardiovascu-
lar complications, such as myocardial damage, atrial 
fibrillation (AF), and stroke. Furthermore, patients 
with pre-existing health conditions such as obesity, 
pulmonary disease, hypertension and heart failure 
are at higher risk for a more severe infection by 
SARS-CoV-2. The disease can trigger exacerbated 
inflammatory responses that can be challenging for 
patients with heart conditions. 
There is a lack of information about the inci-
dence and the consequences of arrhythmias related 
to the virus. As with any infection, there can be an 
increase of stress on the body from which arrhyth-
mias can arise [1]. AF is the most common patho-
logic of arrhythmia, and its incidence is increased 
in the presence of an infection [2].
The presence of palpitations has been reported 
as one of the most common initial symptom of the 
covid-19
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disease (7.3%) [3]. In 138 patients from Wuhan 
who were hospitalized with COVID-19-related 
infection, arrhythmias were reported in 17% of the 
general cohort and in 44% of the patients admitted 
to an intensive care unit [4]. The most common 
arrhythmia overall in patients with COVID-19 is 
sinus tachycardia, but the most frequent pathologic 
arrhythmias include AF, atrial flutter and monomor-
phic or polymorphic ventricular tachycardia. The 
prevalence of AF in COVID-19 patients is substan-
tial when combining both pre-existing and new-
onset AF. The onset of AF may be related to elec-
trolyte abnormalities, dehydration and hypoxia [5]. 
Several previous studies have demonstrated that 
new onset atrial arrhythmias are associated with 
increased morbidity and mortality [6, 7]. The out-
comes in patients with new-onset AF, pre-existing 
AF, and sinus rhythm remain unclear in patients 
with COVID-19.
Atrial fibrillation is a common cause of stroke, 
hospitalization and death, whereas anticoagulation 
therapy for the prevention of stroke can trigger 
bleeding events. The management of AF regarding 
the use of antithrombotic therapies in the setting of 
COVID-19 disease, in clinical practice, does not dif-
fer from the routine management [8]. On the other 
hand, coagulopathy is a common abnormality in 
patients with COVID-19 disease and these patients 
seem to have a higher risk of developing thrombo-
embolic events [9]. The balance between embolic 
and bleeding risk in these patients is challenging.
The current study aims to evaluate the impact 
of new-onset AF compared with pre-existing AF 
and sinus rhythm on long-term mortality, stroke, 
and bleeding in COVID patients.
Methods
The present observational single-center re-
view consists of consecutive patients hospitalized 
with COVID-19-related infection in a tertiary 
hospital and prospective follow-up until discharge. 
A total of 160 consecutive patients were enrolled.
Patients hospitalized with COVID-19 infec-
tion between March and April 2020 were studied. 
Inclusion criteria were age > 18 years old and 
diagnosis of COVID-19 confirmed by polymerase 
chain reaction. For comparison purposes, two 
groups were established: the new-onset AF group, 
which constituted consecutive patients with “de 
novo” AF during the hospitalization; and the 
control group, formed by patients in sinus rhythm 
or with previous AF hospitalized with COVID-19 
during the same period. In the present study, the 
groups were defined as new-onset AF and control 
group (with pre-existing AF or sinus rhythm), to 
scrutinize the role of new-onset AF.
No explicit exclusion criteria were defined 
other than valvular AF or mechanic cardiac pros-
theses to avoid selection bias.
All data were captured using a dedicated elec-
tronic case report form. Clinical and therapeutic 
data were collected. The risk of thromboembolic 
and bleeding events was assessed by calculating 
the CHA2DS2-VASc and the HAS-BLED scores in 
all patients, because the international normalized 
ratio (INR) is not pertinent for the use of heparin 
(and no patient was in treatment with warfarin), 
the “labile INR” component from the original 
HAS-BLED score was not included. Therefore, the 
maximum points for this cohort for the HAS-BLED 
score was 8 instead of 9.
The prevalence of new-onset AF was docu-
mented by electrocardiograms, rhythm strips, and 
Holter monitors. Patients were examined and pulse 
tests were performed daily.
Clinical follow-up was performed during the 
hospitalization, with special attention to anticoagu-
lation therapy, and the incidence of embolic and 
bleeding events was monitored.
The primary endpoint was thrombosis, defined 
as a combination of ischemic stroke, systemic em-
bolism and pulmonary embolism. Ischemic stroke 
was considered in the case of an abrupt onset of 
a focal neurological deficit non-attributable to an 
identifiable nonvascular cause and excluded intrac-
ranial bleeding. Systemic embolic event consisted 
on an abrupt episode of arterial occlusion with 
clinical or radiologic documentation in the absence 
of prior instrumentation.
The primary safety outcome for the current 
study included fatal bleeding, bleeding into a criti-
cal organ (intracranial, intraspinal, pericardial, re-
troperitoneal or intramuscular with compartment 
syndrome) or relevant bleeding with a hemoglobin 
drop of ≥ 2 g/dL. The definition of major bleed-
ing events was consistent with the International 
Society of Thrombosis and Hemostasis (ISTH) 
criteria [10].
The study protocol complied with the Dec-
laration of Helsinki and it was authorized by the 
Reference Ethic Committee and the Local Ethic 
Committees of the hospital. Access to the medical 
records was granted for retrospective analysis.
There has been no patient and public involve-
ment in this work.
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Statistics analysis
Variables are presented as number (percent-
age) or mean ± standard deviation (SD), as appro-
priate. Baseline characteristics between the “de 
novo” AF and control groups, were compared with 
the c2 test for discrete variables and the Student 
t-test for continuous variables provided that popu-
lations were normally distributed. Multivariable lo-
gistic analysis was used to determine independent 
predictors of embolic events, including variables 
with statistical significance on univariate analysis 
and potential confounding factors. Observations 
with missing data were excluded from the analysis 
(< 1% from total). Analysis was conducted using 




A total of 160 consecutive patients with 
COVID-19 infection were enrolled, 7.5% with 
new-onset AF (n = 12) and 92.5% in the control 
group (n = 148). In the control group, 30 patients 
had previous diagnostic of AF and the rest of the 
patients (n = 118) were in sinus rhythm.
New-onset AF patients were studied according 
to their baseline characteristics, in-hospital fea-
tures and clinical outcomes. The main demographic 
and clinical characteristics of the study population 
are shown in Table 1. 
New-onset AF was more frequent in older 
patients (p = 0.007), hypertensive (p = 0.04), 
history of previous acute coronary syndrome 
(p = 0.01) and renal dysfunction (p = 0.03). No dif-
ferences were seen regarding other cardiovascular 
risk factors or comorbidities. Baseline embolic 
risk, as assessed by CHA2DS2-VASc, and baseline 
bleeding risk (HAS-BLED) did not show significant 
differences between groups. The chosen anticoagu-
lation therapy was low molecular weight heparin in 
a therapeutic dose (1 mg/kg/12 h), with no differ-
ences between groups (new-onset AF and control 
group). For the rest of the patients hospitalized due 
to COVID-19 infection, low molecular weight hepa-
rin in a prophylactic dosage (40 mg once daily and 
20 mg for patients with severe renal impairment) 
was prescribed. Regarding laboratory parameters, 
higher values of peak D-dimer were recorded in the 
group with “de novo” AF (p = 0.03). Only 7 pa- 
tients had been admitted to the intensive care 
unit in the total sample, 16% (n = 2) in the group 
Table 1. Baseline demographics and patient characteristics.
New onset AF  
(n = 12)




Sex (female) N = 4 (33.3%) N = 60 (40.5%) 0.43
Age (years), mean ± SD 75.9 ± 9.6 64.9 ± 16.3 0.007
Arterial hypertension 9 (75%) 66 (44.6%) 0.04
Diabetes mellitus 3 (25%) 22 (14.9%) 0.28
Previous myocardial infarction 4 (33.3%) 10 (6.8%) 0.01
Congestive heart failure 2 (16.7%) 11 (7.5%) 0.25
Previous stroke/systemic embolism 0 (0%) 12 (8.1%) 0.38
Previous bleeding 1 (8.3%) 9 (6.1%) 0.40
Abnormal liver function 6 (50%) 43 (29.1%) 0.12
Renal dysfunction 5 (41.7%) 22 (14.9%) 0.03
CHA2DS2VASc 1.66±1.51 2.1 ± 1.7 0.39
HAS-BLED 1.19±1.12 1.5 ± 1.3 0.17
Anticoagulation therapy 3 (25%) 33 (22.3%) 0.53
Troponin I [ng/mL] 0.4 ± 1.0 0.5 ± 26.5 0.87
D-dimer [ng/mL] 10833 ± 18959 3642 ± 9936 0.03
Hemoglobin [g/dL] 13.0 ± 0.9 14.2 ± 7.2 0.50
Values are expressed as number (%) unless otherwise indicated; SD — standard deviation; AF — atrial fibrillation; CHA2DS2-VASc — Conges-
tive heart failure, Hypertension, Age > 75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65–74 years, Sex category; HAS-BLED — 
Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly,  
Drugs/alcohol
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of new-onset AF and 3.3% (n = 5) in the control 
group, p = 0.08 (the Fisher exact test).
Both groups received treatment for COVID-19 
according to the hospital protocol at that moment, 
that included hydroxychloroquine and azithromycin 
if there were no contraindications, antiviral, dexa-
methasone if needed and oxygen support, with no 
differences between groups.
Incidence of major outcomes
New-onset AF was a predictor of embolic 
events (p < 0.001) during hospital stay. The in-
cidence of bleeding events during hospitalization 
was also higher in the group with “de novo” AF 
(p = 0.005). When both embolic events and all-cause 
mortality were assessed collectively, new-onset 
AF was related to worse prognosis (p = 0.006). 
The embolic events in the group with new-onset 
AF were one stroke, two systemic embolism 
and one pulmonary embolism, and none of these 
patients were receiving anticoagulation therapy. 
Patients with COVID-19 disease and new-onset 
AF had a higher incidence of bleeding events, and 
gastrointestinal bleeding was the main source of 
hemorrhages in both groups. All-cause mortal-
ity during the admission showed no differences 
between the groups. The hospital stay was longer 
in the group with new-onset AF (p < 0.001). The 
events in the population are shown in Table 2.
In multivariate analysis, only the new onset of 
AF remained an independent predictor of embolic 
events, carrying a risk 14.26 times higher than 
in the control group (95% confidence interval 
2.86–71.10, p < 0.001). The multivariate analysis is 
shown in Table 3. The characteristics of the group 
with new-onset AF are shown in Table 4.
Discussion
The present study shows that: 
 — New-onset of AF during hospital stay in pa-
tients with COVID-19 is an independent pre-
dictor of in-hospital embolic events;
 — New-onset AF is associated with worse clini-
cal features during hospitalization in terms of 
more bleeding events, and more events in the 
combined end-point (death + embolic events);
 — New-onset AF is associated with a longer 
hospital stay.
Atrial fibrillation is a common cause of stroke 
and embolism, especially when it is not treated with 
anticoagulation therapy when indicated, as preven-
tion of stroke. On the other hand, COVID-19 may 
predispose patients to thrombotic disease, both in 
the venous and arterial circulations, due to exces-
sive inflammation, platelet activation, endothelial 
dysfunction, and stasis [11]. Preliminary reports 
suggest that hemostatic abnormalities, including 
disseminated intravascular coagulation, occurs in 
patients affected by COVID-19 [12]. This makes 
management challenging because of anticoagula-
tion therapy in patients with both conditions.
It remains unclear whether hemostatic chang-
es are a specific effect of SARS-CoV-2 or are 
a consequence of cytokine storm that precipitates 
the onset of systemic inflammatory response syn-
drome, as observed in other viral diseases [13].
It is already known that thrombogenic phe-
nomenon in AF is not only limited to local factors 
Table 2. Events during hospitalization in patients with COVID-19. 
Events New-onset atrial  
fibrillation (n = 12)




Embolic events 5 (41.7%) 6 (4.1%) < 0.001
Bleeding events 4 (33.3%) 7 (4.7%) 0.005
All-cause mortality 4 (33.3%) 26 (17.6%) 0.16
Death + embolic event 7 (58.3%) 29 (19.6%) 0.006
Days of admission 16.4 ± 13.0 8.6 ± 6.5 < 0.001
Table 3. Independent predictors of embolic 






New onset AF 14.26 2.86–71.10 < 0.001
Age 1.00 0.95–1.06 0.65
Arterial hypertension 2.04 0.40–10.29 0.26
Renal dysfunction 0.38 0.04–3.03 0.41
Bleeding events 1.82 0.21–15.66 0.96
AF — atrial fibrillation; CI — confidence interval
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such as stasis or a dysfunctional atrium contrac-
tion. A generalized hypercoagulable state has been 
proposed, too. This may lead to concern that other 
proinflammatory and procoagulant situations, such 
as cancer or infections could have a synergic effect 
on cardiovascular events [14].
New-onset AF was associated with a higher 
incidence of embolic events, and this was regard-
less of the use of anticoagulation (there are no 
significant differences between the groups). How-
ever, the rate of bleeding events was also higher, 
and this points out that the onset of AF probably 
indicates a more inflammatory scenario, with more 
severe hypoxia and a more important coagulopathy 
in patients with “de novo” AF.
The use of anticoagulation with a therapeutic 
dosage is not recommended in general for all pa-
tients with COVID-19, if they do not have AF or 
other indications. In the present study, bleeding 
events were more frequent in patients with antico-
agulation, with no differences between the groups 
(new-onset AF and control group). However, the 
incidence of embolism was higher in patients with 
new-onset AF (41.7%). All patients with embolic 
events in our sample were not receiving anticoag-
ulation therapy (with a therapeutic dosage). If we 
look at the control group, patients with AF were 
correctly treated with anticoagulation therapy, 
and no embolic events were observed. All the 
events in this group corresponded to patients with 
sinus rhythm and without anticoagulation therapy 
(4.1%). The majority of patients with new-onset 
AF were not receiving anticoagulation therapy 
(75%, 9 patients). This can be explained because 
the diagnosis of AF was after the embolic event 
(in 5 patients), and because of high bleeding risk 
(in 4 patients).
Thus, it would be of interest to identify predic-
tors for the onset of AF, in order to manage the chal-
lenging balance between embolic and bleeding risk. 
A variety of further factors, including congestive 
heart failure, ischemic heart disease and hyperten-
sion have been addressed as potential co-factors for 
the development of new-onset AF in critically ill 
patients [15]. In the current study, similar factors 
like age, arterial hypertension, history of myo-
cardial infarction, renal dysfunction and a higher 
value of D-dimer, acted as possible co-factors for 
the new onset of AF in patients with COVID-19. 
The present data support the hypothesis that these 
factors might play a major role in the development 
of AF in COVID-19 patients.
New onset of AF is common in several dis-
eases and, on the other hand, it has been associated 
Table 4. Characteristics of patients with COVID-19 infection and new-onset atrial fibrillation.
Patient Age  
(years-old)








1 74 4 1 Low molecular weight heparin  
(1 mg/kg/24 h)
No events No events
2 82 6 2 Prophylactic heparin No events No events
3 57 15 0 Prophylactic heparin No events No events
4 88 7 3 Low molecular weight heparin  
(1 mg/kg/24 h)
No events No events
5 82 14 2 Prophylactic heparin No events No events
6 82 38 2 Prophylactic heparin Systemic  
embolism
No events
7 82 12 2 Prophylactic heparin Systemic  
embolism
No events
8 58 8 1 Prophylactic heparin No events Gastrointestinal 
bleeding
9 73 17 1 Prophylactic heparin Pulmonary 
embolism
Epistaxis
10 75 28 2 Prophylactic heparin Stroke Gastrointestinal 
bleeding
11 76 40 2 Prophylactic heparin Stroke Gastrointestinal 
bleeding
12 82 8 2 Low molecular weight heparin  
(1 mg/kg/24 h)
No events No events
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with an increased incidence of other complications 
including stroke, increased hospital length of stay 
and increased cost of hospitalization. Prevention 
of AF has been a reasonable clinical goal, conse-
quently, many randomized trials have evaluated 
the effectiveness of pharmacological and non- 
-pharmacological interventions in other patholo-
gies, such as cardiac surgery [16–20].
It has been shown that agents with anti-in-
flammatory and antioxidant properties decreased 
postoperative AF rates in previous studies. Further 
studies are needed in order to identify predictors and 
potential treatments that might be useful for patients 
with “de novo” AF in the context of COVID disease. 
The pathophysiological mechanism underlying the 
development of AF and the incidence of embolic 
events in COVID-19 patients is not known. However, 
the systemic inflammatory response per se, could be 
a trigger for both conditions in COVID-19 patients.
Is the development of the arrhythmia just 
a marker of the severity of the infection? Does the 
onset of AF imply per se, a higher incidence of 
embolic and bleeding events? Little is known about 
triggers that could modify the coagulation cascade 
in patients with COVID-19, but hemostatic changes 
are common during the infection.
Limitations of the study
The number of patients studied with new-onset 
AF was small, which could limit the number of in-
dependent predictors identified and the consistency 
of the results. However, the statistical difference is 
such that it allows drawing preliminary conclusions.
Conclusions 
Patients with new-onset AF in the context of 
COVID-19 disease have worse prognosis in terms 
of higher incidence of embolic events. The onset of 
AF has implications in patients with COVID-19 that 
go beyond the simple presence of the arrhythmia, 
and the outcomes in these patients is worse than 
in patients with previous AF (and, of course, than 
patients in sinus rhythm). Patients with “de novo” 
AF also have a higher incidence of bleeding events, 
and a longer hospital stay. Further investigations 
are needed to enable strategies that may predict 
the new onset of AF, in order to identify high risk 
patients, provide an early treatment and thus mini-
mize the embolic risk of COVID-19 and AF.
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